- 2024.
- 2023.
- 2022.
- 2021.
- 2020.
- 2019.
- 2018.
- 2017.
- 2016.
- 2015.
- 2014.
- 2013.
- 2012.
- 2011.
- 2010.
- 2009.
- 2008.
- 2007.
- 2006.
- 2005.
- 2004.
- 2003.
- 2002.
- 2001.
- 2000.
- 1999.
- 1998.
- 2024.
- 2023.
- 2022.
- 2021.
- 2020.
- 2019.
- 2018.
- 2017.
- 2016.
- 2015.
- 2014.
- 2013.
- 2012.
- 2011.
- 2010.
- 2009.
- 2008.
- 2007.
- 2006.
- 2005.
- 2004.
- 2003.
- 2002.
- 2001.
- 2000.
- 1999.
- 1998.
2009.
-
- Dec.11.2009
- Launch of a Type 2 Oral Antidiabetic Drug, GLACTIV® Tablet(19 KB)
-
- Dec.11.2009
- Launch of Antiemetic Drug, EMEND® Capsule(17 KB)
-
- Oct.16.2009
- Approval Received for a Type 2 Oral Antidiabetic Drug Glactiv® Tablet(16 KB)
-
- Oct.16.2009
- Approval Received for Antiemetic Drug EMEND® Capsule(16 KB)
-
- Oct.15.2009
- Ono Signs New Drug Discovery Agreement with Evotec AG Targeting an Ion Channel(15 KB)
-
- Sep.02.2009
- License Agreement of a Drug Candidate for Irritable Bowel Syndrome with Tioga(9 KB)
-
- Jun.02.2009
- Data from ongoing Phase 1 expansion cohort and Multi-Dose Phase 1b Trials of Investigational Fully Human Anti-PD-1 Antibody “ONO-4538/MDX-1106” in Cancer Patients at American Society of Clinical Oncology Annual Meeting(32 KB)
-
- May.13.2009
- Partial Revisions to the Articles of Incorporation(173 KB)
-
- May.13.2009
- Announcement on Changes of Representative Directors and Members of the Board of Directors(174 KB)
-
- Apr.06.2009
- Launch of the Osteoporosis Treatment, RECALBON® Tablets / Bonoteo® Tablets(15 KB)
-
- Mar.12.2009
- Ono Enters into Drug Discovery Agreement on Ion Channel Targets with Xention(13 KB)
-
- Jan.21.2009
- Ono Approval for the Osteoporosis Treatment, RECALBON® Tablets / Bonoteo® Tablets(13 KB)